Englewood Lab (A950140) Q2 2024 earnings summary

Executive summary

• Operates as a cosmetics ODM/OEM manufacturer in the US, specializing in skincare and functional cosmetics, with a strong R&D focus and global certifications.

• Maintains a single consolidated subsidiary in Korea, fully owned, with no changes in group structure during the period.

• Listed on KOSDAQ since 2016, with stable ownership and no significant legal or regulatory issues reported.

Financial highlights

• Consolidated H1 2024 revenue: $73.1M, down from $158.4M in FY2023 and $117.3M in FY2022.

• H1 2024 operating income: $8.1M; net income: $8.4M; basic EPS: $0.42.

• Gross margin improved to 21.3% in H1 2024 from 13.9% in FY2023.

• Cash and equivalents at period end: $7.3M; total assets: $128.0M; equity: $93.9M.

• Dividend paid: $1.49M in H1 2024.

Outlook and guidance

• Focus on expanding premium skincare market share and targeting global top-tier brands.

• Continued investment in R&D and regulatory compliance to support innovation and export growth.